Preprint · OA
via OpenAlex
MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE
Lennart Langenhoff, Jonas Simon, Sandrina Weber, Diana Hubert, Martin Schuler, Marvin Mann, Vuk Puzovic, Grischa Gerwert, Adrian Höveler, Léon Beyer, Lars Tönges, Carsten Kötting, Jörn Güldenhaupt, Brit Mollenhauer, Klaus Bernhard Gerwert
medRxiv · 2025 · ▲ 3 citations
Abstract
Abstract Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are characterized by pathological aggregation of misfolded alpha-synuclein (αSyn) in the central and peripheral nervous systems. Seed amplification assays (SAAs) can detect misfolded αSyn in cerebrospinal fluid (CSF), allowing a more precise biological classification of these diseases. Translating biomarker-based diagnostics to blood represents a crucial milestone to democratize access to molecular testing, as blood sampling is minimally invasive and widely scalable. However, current blood-based SAA approaches require extensive sample preprocessing, which introduces variability and has yielded inconsistent results. Here, we present the immuno-infrared-sensor (iRS) platform, which detects misfolded αSyn directly in blood serum without sample preprocessing and without amplification. The iRS measures the secondary-structure distribution of αSyn by distinguishing α-helical/random-coil monomers from β-sheet-rich oligomers and fibrils. This conformational distribution reflects disease-associated structural changes in blood and provides information beyond the binary readout of SAAs. In a combined cohort (n = 127) consisting of 74 individuals with synucleinopathies (PD, DLB, MSA and isolated rapid eye movement sleep behavior disorder (iRBD)) and 53 controls, the assay achieved a receiver operating characteristic area under the curve (ROC AUC) of 0.94 (95% confidence interval (CI), 0.88–0.99), with 88% sensitivity and 89% specificity in serum using a dual-threshold classification that categorized individuals as controls (no misfolding, green), at risk (low misfolding, yellow) or diseased (high misfolding, red). By extending the iRS platform from CSF to blood serum, this study demonstrates αSyn misfolding as a promising blood-based structural biomarker for synucleinopathies. The iRS assay provides a broadly applicable platform technology for more precise biological classification, disease monitoring and assessment of drug response for PD in peripheral blood.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.64898/2025.12.19.25342662
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Langenhoff, L., Simon, J., Weber, S., Hubert, D., Schuler, M., Mann, M., Puzovic, V., Gerwert, G., Höveler, A., Beyer, L., Tönges, L., Kötting, C., Güldenhaupt, J., Mollenhauer, B., & Gerwert, K.B. (2025). MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE. <em>medRxiv</em>. https://doi.org/10.64898/2025.12.19.25342662
Vancouver
Langenhoff L, Simon J, Weber S, Hubert D, Schuler M, Mann M, et al. MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE. medRxiv. 2025. doi:10.64898/2025.12.19.25342662.
BibTeX
@unpublished{lennart2025MISFOL,
title = {MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE},
author = {Lennart Langenhoff and Jonas Simon and Sandrina Weber and Diana Hubert and Martin Schuler and Marvin Mann and Vuk Puzovic and Grischa Gerwert and Adrian Höveler and Léon Beyer and Lars Tönges and Carsten Kötting and Jörn Güldenhaupt and Brit Mollenhauer and Klaus Bernhard Gerwert},
journal = {medRxiv},
year = {2025},
doi = {10.64898/2025.12.19.25342662},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Movement Disorders 2024
Open access · CC-BY
Detecting Misfolded α‐Synuclein in Blood Years before the Diagnosis of Parkinson's Disease
Movement Disorders 2019
Open access · CC-BY
Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease
Research Square 2021
Preprint · CC-BY
Mitochondrial Biogenesis, Telomere Length and Cellular Senescence in Parkinson’s Disease and Lewy Body Dementia
Frontiers in Neurology 2022
Open access · CC-BY
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
Scientific Reports 2025
Open access · CC-BY
Alpha-synuclein is increased in erythrocytes in parkinson’s disease cases
Molecular Neurodegeneration 2011
Open access · CC-BY